Please assess the completion status of the following clinical trial:

Trial Title: Fosaprepitant Dimeglumine and Granisetron Transdermal System in Preventing Nausea and Vomiting in Patients With Breast Cancer Undergoing Chemotherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically confirmed breast cancer scheduled to receive chemotherapy with doxorubicin and cyclophosphamide (adjuvant or neoadjuvant)~* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1~* Projected life expectancy of at least 3 months~* Provision of informed consent prior to any study-related procedures~* Negative pregnancy test for women of childbearing potential~* Absolute neutrophil count (ANC) \>= 1500/mm\^3~* Platelet count \>= 100,000 cells/mm\^3~* Hemoglobin \>= 9.0g/dL~* Serum creatinine =\< 1.5 mg/dl~* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =\< 2.5 X upper limit of normal (ULN)~* Alkaline phosphatase =\< 2.5 X upper limit of normal; in patients with bone metastasis and no evidence of liver metastasis and bilirubin =\< upper limit of normal an alkaline phosphatase =\< 5 ULN will be allowed~* Serum bilirubin =\< 1.0 mg/dL~* No other concomitant therapy directed at the cancer is allowed~Exclusion Criteria:~* Allergy or intolerance to 5HT3 or NK-1 antagonists and dexamethasone~* Use of another antiemetic agent (5HT3 antagonists, phenothiazines, butyrophenones, cannabinoids, metoclopramide, or corticosteroids) within 72 hours prior to day 1 of the study~* Use of anticoagulant agent (Warfarin, Coumadin, Jantoven, Marevan, Lawarin, Waran, or Warfant)~* An episode of vomiting or retching within 24 hours before the start of the initial treatment with chemotherapy~* Severe concurrent illness other than neoplasia~* Gastrointestinal obstruction or an active peptic ulcer~* Patients who are pregnant or breast feeding because aprepitant may be harmful to the developing fetus and newborn

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive care (antiemetics) (Type: EXPERIMENTAL): Patients receive granisetron transdermal system patch 24-48 hrs before the initiation of chemotherapy. Patients wear the granisetron transdermal system patch for 7 days. Patients receive fosaprepitant dimeglumine IV over 15 minutes on day 1 of chemotherapy. Treatment repeats every 2 or 3 weeks for up to 4 courses in the absence of unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).